grant
Neurosurgical Oncology Unit
Organization NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKELocation UNITED STATES
NIHUS FederalResearch GrantFY2025AbscissionApicalAssayB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BioassayBioinformaticsBiological AssayBrain CancerCancersCell BodyCell Communication and SignalingCell CycleCell Division CycleCell Growth in NumberCell LineCell LocomotionCell MigrationCell MovementCell MultiplicationCell ProliferationCell SignalingCellLineCellsCellular MigrationCellular MotilityCellular ProliferationCharacteristicsCiliaDataDevelopmentDiseaseDisorderExcisionExtirpationGene ExpressionGenesGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaHPGFHepatocyte-Stimulating FactorHumanHybridoma Growth FactorIFN-beta 2IFNB2IL-6IL6 ProteinImmune mediated therapyImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyImpairmentInterleukin-6Intracellular Communication and SignalingMGI-2Malignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMammalian CellMediatingMicro-tubuleMicrotubulesModern ManMolecularMorphologyMyeloid Differentiation-Inducing ProteinMyeloid-derived suppressor cellsNeuroglial NeoplasmNeuroglial TumorNewly DiagnosedOncologyOncology CancerOrganellesPathogenesisPathway interactionsPatientsPlasmacytoma Growth FactorPlayPrognostic MarkerProliferatingProteinsPublishingRadiation therapyRadiotherapeuticsRadiotherapyRegulationRemovalResearch ActivityResistanceRoleSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStrains Cell LinesSurfaceSurgical RemovalTemodalTemodarTumor-DerivedUpdateWorkWound Repairbiological signal transductioncell motilitychemo-/radio-therapychemo-radiotherapychemoradiationchemoradiation therapychemoradiation treatmentchemoradiotherapyciliogenesiscilium biogenesisclinical relevanceclinically relevantcultured cell linedevelopmentalextracellular vesiclesglial-derived tumorglioblastoma multiformeimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive myeloid cellsimmunosuppressive responseinterferon beta 2knock-downknockdownmalignancymethazolastonemyeloid suppressor cellsmyeloid-derived suppressive cellsneoplasm/cancerneuroglia neoplasmneuroglia tumorneurosurgerynew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyparticlepathwayprognostic biomarkerprognostic indicatorpublic data basepublic databasepublicly accessible data basepublicly accessible databasepublicly available data basepublicly available databaseradiation treatmentradio-chemo-therapyradio-chemotherapyradiochemotherapyresectionresistantresponsesocial rolespongioblastoma multiformestable cell linestandard of caresuppressive myeloid cellstemozolomidetreatment with radiationtumorwound healingwound recoverywound resolution
Description preview
INTRODUCTION:
Glioblastoma is the most common primary malignant brain tumor. The disease is uniformly fatal with a median overall survival of only 15 months. The current standard of care for newly diagnosed glioblastoma is maximal safe resection, radiotherapy, and temozolomide. The primary cilium is a microtubule-based organelle present on the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click